GLP-1 drugs like Ozempic may reduce cancer risk

A study published in JAMA Network Open suggests that GLP-1 drugs like Ozempic may reduce the risk of obesity-related cancers in type 2 diabetes patients. Researchers analyzed 1.6 million patients and found a significant risk reduction in 10 out of 13 types of cancers. GLP-1 treatments mimic a blood sugar-regulating hormone. Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are popular GLP-1 drugs with weight loss benefits. Further research on cancer prevention benefits is recommended.